PF-06282999

• Description :

  PF-06282999 is a potent and selective myeloperoxidase inhibitor which is potential useful for the treatment of cardiovascular diseases.

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Glutathione Peroxidase

• Type :

  Reference compound

• Related Pathways :

  Apoptosis; Metabolic Enzyme/Protease

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Cardiovascular Disease

• Assay Protocol :

  https://www.medchemexpress.com/PF-06282999.html

• Purity :

  99.02

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  O=C(N)CN(C(C1=CC(Cl)=CC=C1OC)=C2)C(NC2=O)=S

• Molecular Formula :

  C13H12ClN3O3S

• Molecular Weight :

  325.77

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Dong JQ, et al. Pharmacokinetics and Disposition of the Thiouracil Derivative PF-06282999, an Orally Bioavailable, Irreversible Inactivator of Myeloperoxidase Enzyme, Across Animals and Humans. Drug Metab Dispos. 2016 Feb;44 (2) :209-19.|[2]Ruggeri RB, et al. Discovery of 2- (6- (5-Chloro-2-methoxyphenyl) -4-oxo-2-thioxo-3,4-dihydropyrimidin-1 (2H) -yl) acetamide (PF-06282999) : A Highly Selective Mechanism-Based Myeloperoxidase Inhibitor for the Treatment of Cardiovascular Diseases. J Med Chem. 20

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 1

• CAS Number :

  [1435467-37-0]